Screener
Beta Bionics BBNX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from the issuance of common stock from private placement, net of issuance costs | — | 15,591 |
| Proceeds from stock option exercises and employee stock purchase plan issuances | 2,424 | 140 |
| Net cash provided by financing activities | 2,424 | 211,161 |
| Net increase in cash, cash equivalents and restricted cash | 12,742 | 4,643 |
| Cash, cash equivalents and restricted cash at beginning of period | 31,676 | 30,532 |
| Cash, cash equivalents and restricted cash at end of period | $44,418 | $35,175 |
| Supplemental disclosure of non-cash investing and financing information: | ||
| Reclassification of long-term investments to short-term investments | $45,322 | $79,838 |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's net change in cash?
- Beta Bionics (BBNX) reported net change in cash of $14.11M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Beta Bionics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude